Back to search results

A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia

Abroad (travel likely)RecruitingPHASE2, PHASE3

Conditions

Narcolepsy Type 1 · Narcolepsy Type 2 · Idiopathic Hypersomnia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Alkermes Investigator Site, Phoenix, Arizona, United States

  • Alkermes Investigational Site, Little Rock, Arkansas, United States

  • Alkermes Investigational Site, Los Angeles, California, United States

  • Alkermes Investigator Site, San Francisco, California, United States

  • Alkermes Investigational Site, Stanford, California, United States

  • Alkermes Investigational Site, Colorado Springs, Colorado, United States

  • Alkermes Investigational Site, Brandon, Florida, United States

  • Alkermes Investigational Site, Miami, Florida, United States

  • Alkermes Investigational Site, Winter Park, Florida, United States

  • Alkermes Investigational Site, Atlanta, Georgia, United States

  • Alkermes Investigational Site, Macon, Georgia, United States

  • Alkermes Investigational Site, Stockbridge, Georgia, United States

  • Alkermes Investigational Site, Peoria, Illinois, United States

  • Alkermes Investigational Site, Lansing, Michigan, United States

  • Alkermes Investigational Site, Sterling Heights, Michigan, United States

  • Alkermes Investigational Site, Lincoln, Nebraska, United States

  • Alkermes Investigational Site, Middletown, New Jersey, United States

  • Alkermes Investigational Site, Denver, North Carolina, United States

  • Alkermes Investigational Site, Huntersville, North Carolina, United States

  • Alkermes Investigational Site, Canton, Ohio, United States

  • Alkermes Investigational Site, Cincinnati, Ohio, United States

  • Alkermes Investigational Site, Cincinnati, Ohio, United States

  • Alkermes Investigational Site, Dublin, Ohio, United States

  • Alkermes Investigational Site, Abington, Pennsylvania, United States

  • Alkermes Investigational Site, Wyomissing, Pennsylvania, United States

  • Alkermes Investigational Site, Columbia, South Carolina, United States

  • Alkermes Investigational Site, Austin, Texas, United States

  • Alkermes Investigational Site, San Antonio, Texas, United States

  • Alkermes Investigational Site, Sugar Land, Texas, United States

  • Alkermes Investigational Site, Madison, Wisconsin, United States

  • Alkermes Investigational Site, Sydney, New South Wales, Australia

  • Alkermes Investigational Site, Bedford Park, South Australia, Australia

  • Alkermes Investigational Site, Clayton, Victoria, Australia

  • Alkermes Investigational Site, Bruges, Brugge, Belgium

  • Alkermes Investigational Site, Alken, Belgium

  • Alkermes Investigational Site, Namur, Belgium

  • Alkermes Investigational Site, Prague, Czechia

  • Alkermes Investigational Site, Montpellier, Herault, France

  • Alkermes Investigational Site, Bordeaux, France

  • Alkermes Investigational Site, Bologna, Italy

  • Alkermes Investigational Site, Milan, Italy

  • Alkermes Investigational Site, Verona, Italy

  • Alkermes Investigational Site, Zwolle, Netherlands

  • Alkermes Investigational Site, Madrid, Madrid, Spain

  • Alkermes Investigational Site, Barcelona, Spain

  • Alkermes Investigational Site, Madrid, Spain

Study leads

  • Medical Director

    Study Director

    Alkermes, Inc.

View source on ClinicalTrials.gov(opens in a new tab)